Search Results
Nov 07, 2025, 09:00 ET Diakonos Oncology Presents Promising Preliminary Data from Phase 1 Study of DOC1021 Cell-Based Immunotherapy in Pancreatic Cancer at Society for Immunotherapy of Cancer 40th Annual Meeting
Professor of Medicine-Hematology & Oncology, Barry Stephen Smith Memorial Endowed Professor, and Medical Director of Medical Oncology of the Dan L Duncan Comprehensive Cancer Center at the Baylor College of Medicine. "We are now enrolling a second group of patients where DOC1021 is given after surgery
More news about: Diakonos Oncology
Nov 07, 2025, 08:52 ET Weltweit erste, auf APOC3 abzielende Gen-Editing-Therapie zur Behandlung von Hyperlipidämie
Der Patient, bei dem eine Chylomikronämie diagnostiziert wurde, hatte eine lange Vorgeschichte mit Nüchtern-Triglyceridwerten (TG) von über 12,5 mmol/L und wiederkehrender akuter Pankreatitis. In der Dosiseskalationsstudie für CS-121 sank sein Nüchtern-TG-Spiegel innerhalb von drei Tagen nach einer
More news about: CorrectSequence Therapeutics
Nov 07, 2025, 08:31 ET MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025
In addition to its glycemic effects, vanoglipel significantly decreased plasma ALT levels in subjects with baseline ALT between 40 and 200 U/L. The reduction in ALT was not further enhanced by co-administration with a DPP4 inhibitor, suggesting that vanoglipel monotherapy drives the majority
More news about: MetaVia Inc.
Nov 07, 2025, 08:30 ET Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine
(BRII-179-835-001) were categorized as BRII-179 anti-HBs responders or non-responders based on peak hepatitis B surface antibody (anti-HBs) levels (≥10 IU/L or <10 IU/L, respectively), and subsequently received 48 weeks of elebsiran (100 mg Q4W) plus weekly PEG-IFNα in the ENSURE study. Key
More news about: Brii Biosciences Limited
Nov 07, 2025, 08:26 ET AION UT在澳門正式上市，廣汽深度踐行「澳門ACTION」加速生態出海
UT正式在澳門上市。這款面向全球市場打造的智能生活座駕，造型時尚、空間寬敞，具備領先的智能化和超強的安全品質，為澳門消費者帶來超值體驗。 展會現場，AION UT吸引了眾多觀眾駐足體驗，觀眾對這款車的米蘭時尚大掀背造型以及媲美豪華轎車的舒適駕乘空間表示讚賞，並認為智能語音交互、L2級輔助駕駛系統等豐富的科技配置超出預期。有澳門汽車專業媒體表示，AION UT車型在設計、空間表現和智能化等方面表現突出，契合澳門道路環境以及本地消費者對高品質純電小車的需求，預計將收穫良好的市場反響。 廣汽在本次澳門車展的設計
More news about: GAC
Nov 07, 2025, 08:24 ET La primera terapia de edición genética del mundo dirigida a APOC3 para la hiperlipidemia
El paciente, diagnosticado con quilomicronemia, tenía una larga historia de niveles de triglicéridos (TG) en ayunas superiores a 12,5 mmol/L y pancreatitis aguda recurrente. En el IIT de aumento de dosis para CS-121, su nivel de TG en ayunas disminuyó significativamente dentro de los tres
More news about: CorrectSequence Therapeutics
Nov 07, 2025, 08:05 ET International Tower Hill Mines Files 2025 Third Quarter Financial Results
Alaska. On behalf ofInternational Tower Hill Mines Ltd. (signed) Karl L. HannemanChief Executive Officer This news release is not, and is not to be construed in any
More news about: International Tower Hill Mines Ltd.
Nov 07, 2025, 07:00 ET Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress
with a least squares mean (LSM) difference of -0.02 mmol/L（95% confidence interval (CI): -0.10, 0.06）[-0.06 mg/dL (95% CI: -0.31, 0.20)]; the upper CI bound of 0.06 mmol/L (0.20 mg/dL) was below the pre-defined non-inferiority margin (NIM) of 0.19 mmol/L (0.59 mg/dL). (see Figure 1)
More news about: Alebund Pharmaceuticals
Nov 07, 2025, 07:00 ET Calumet Reports Third Quarter 2025 Results
the impact of liquidation of inventory layers calculated using the LIFO method; (j) RINs mark-to-market adjustments; (k) RINs incurrence expense; and (l) all extraordinary, unusual or non-recurring items of gain or loss, or revenue or expense. We define Adjusted EBITDA with Tax Attributes
More news about: Calumet, Inc.
Nov 07, 2025, 07:00 ET Enbridge Reports Strong Third Quarter Results, Announces Accretive Investments and Reaffirms 2025 Financial Guidance
Preference Shares, Series L
More news about: Enbridge Inc.
Nov 07, 2025, 06:57 ET GORE ANNOUNCES POSITIVE CLINICAL TRIAL RESULTS OF THE INVESTIGATIONAL GORE® VIABAHN® FORTEGRA VENOUS STENT FOR TREATMENT OF PATIENTS WITH DEEP VENOUS ILIOCAVAL OBSTRUCTION
LAS VEGAS and FLAGSTAFF, Ariz., Nov. 7, 2025 /PRNewswire/ -- W. L. Gore & Associates' medical business (Gore) today announced trial results evaluating the investigational GORE® VIABAHN® FORTEGRA
More news about: W. L. Gore & Associates, Inc. MPD Division
Nov 07, 2025, 06:57 ET NYU Langone Cardiologists Share Leading Research at AHA Scientific Sessions 2025 & Dr. Judith S. Hochman Honored with Research Achievement Award
Harmony R. Reynolds, MD, the Joel E. and Joan L. Smilow Professor of Cardiology and director of NYU Langone's Cardiovascular Clinical Research Center, focuses on MINOCA, myocardial infarction with non-obstructive
More news about: NYU Langone Health
Nov 07, 2025, 06:41 ET AION UT Officially Launched in Macao, GAC Deeply Implements 'Macao ACTION' to Accelerate Ecological Globalization
comfortable riding space comparable to that of luxury sedans, and believed that the rich technological configurations such as intelligent voice interaction and L2-level advanced driver assistance system exceeded expectations. Macao's professional automobile media stated that the AION UT performs outstandingly in
More news about: GAC
Nov 07, 2025, 06:23 ET AION UT Officially Launched in Macao, GAC Deeply Implements 'Macao ACTION' to Accelerate Ecological Globalization
comfortable riding space comparable to that of luxury sedans, and believed that the rich technological configurations such as intelligent voice interaction and L2-level advanced driver assistance system exceeded expectations. Macao's professional automobile media stated that the AION UT performs outstandingly in
More news about: GAC
Nov 07, 2025, 04:30 ET LEPAS Elegant Technology Safeguards Every Elegant Journey with Global Five-Star Safety Standards
seasons, the LEPAS L8 is engineered with a wading depth over 600 mm for secure passage through water-logged roads. Rollover scenarios—responsible for 20% of single-vehicle accidents—also undergo comprehensive validation. At the 2025 Chery International User Summit, the flagship LEPAS L8 completed underbody-scrape,
More news about: Chery Group
Nov 07, 2025, 04:01 ET LEPAS優雅科技以全球五星安全標準，守護每一段優雅旅程
優雅科技的安全設計更深度貼合全球用戶的真實生活場景。通過事故調查發現，車速30-70km/h時車輛刮底損壞概率更高，品牌針對性優化底盤防護；針對東南亞長期多雨環境，LEPAS L8全系按涉水深度>600mm開發，從容應對積水路段；面對占單車事故20%、乘員受傷率高15%-20%的翻滾工況，更是進行全方面驗證。在2025奇瑞國際用戶生態大會首次公開的安全實驗上，品牌旗下旗艦車型LEPAS L8，以出色的表現完成了刮底、涉水、碰撞翻滾三大嚴苛測試，完美詮釋了LEPAS在安全領域的硬核實力。此外，多項主動安全功能與泊車輔助系統，讓「優雅駕控」全程可控。 為實現這一嚴苛安全目標，優雅科技依托奇瑞集團涵蓋全球各個國家和地區的最高開發標準，在集團覆蓋全人員、全過程、全工況、全方位、全市場的全維安全防護體系框架之下，致力於為全球用戶提供全方位的安全保障。
More news about: 奇瑞集團
Nov 07, 2025, 03:47 ET LEPAS Elegant Technology Safeguards Every Elegant Journey with Global Five-Star Safety Standards
seasons, the LEPAS L8 is engineered with a wading depth over 600 mm for secure passage through water-logged roads. Rollover scenarios—responsible for 20% of single-vehicle accidents—also undergo comprehensive validation. At the 2025 Chery International User Summit, the flagship LEPAS L8 completed underbody-scrape,
More news about: Chery Group
Nov 07, 2025, 02:40 ET TAILG, 3년 연속으로 밀라노에서 별이 되다...글로벌 전기 모빌리티의 신흥 강자로 우뚝
TAILG는 글로벌 저탄소 모빌리티 연구소(Global Low-Carbon Mobility Research Institute)의 지원 속에 나트륨 이온 배터리, 수소 에너지, 고속 충전 및 자율 주행 분야에서 전진을 계속하고 있다.이번 전시회에서 F73L 자율 주행 데모는 정밀도와 제어력으로 보는 이에게 깊은 인상을 남겼다. TAILG는 또 개방형 혁신을 받아들여 IoT 차량 연결과 관련해서는 화웨이와, 주행 거리와 안전성을 높여 주는 첨단 배터리 시스템과 관련해서는 BYD와 파트너십을
More news about: TAILG
Nov 07, 2025, 02:00 ET Lunai Bioworks réussit à éliminer complètement les tumeurs pancréatiques primaires et secondaires dans des modèles humanisés précliniques, marquant une avancée significative pour l'immunothérapie allogénique contre le cancer
la première fois une puissante activité antitumorale des CD34+ dérivées de cellules souches hématopoïétiques (CSH) et modifiées pour surexprimer les CD40L, CD93 et CXCL13 dans des modèles murins humanisés de cancer du pancréas. Alors que l'étude initiale utilisait un vecteur lentiviral de qualité recherche,
More news about: Lunai Bioworks Inc.
Nov 07, 2025, 02:00 ET Lunai Bioworks logra la regresión completa de tumores pancreáticos primarios y metastásicos
actividad antitumoral de las células dendríticas (DC) derivadas de células madre hematopoyéticas (HSC) CD34+, modificadas genéticamente para sobreexpresar CD40L, CD93 y CXCL13 en modelos de ratón humanizados de cáncer de páncreas. Si bien el estudio inicial utilizó un vector lentiviral de grado de investigación,
More news about: Lunai Bioworks Inc.
Nov 07, 2025, 01:47 ET ミラノで3年連続の輝きを放つ TAILG、世界の電動モビリティに新たな波をリード
グローバル低炭素モビリティ研究所の支援を受け、TAILG はナトリウムイオン電池、水素エネルギー、急速充電、自動運転の分野で前進しています。 展示会では、F73L の自律走行デモがその精密さと制御力で観客を魅了しました。 TAILG はオープンイノベーションも推進しており、Huawei と IoT 車両接続で提携し、BYD と先進バッテリーシステムで協力して航続距離と安全性を向上させています。
More news about: TAILG
Nov 07, 2025, 01:00 ET Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development
antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody
More news about: Harbour BioMed
Nov 06, 2025, 21:22 ET 世界初の APOC3 を標的とした高脂血症向け遺伝子編集治療薬
ける両アレル突然変異によって引き起こされる稀な常染色体劣性疾患であり、空腹時トリグリセリド（TG）が10 mmol/L（885 mg/dL）以上、世界的な有病率は10万人に1人〜100万人に1人とされています。MCSは、遺伝的要因、生活習慣、または代謝性疾患の複雑な相互作用によって発症し、世界的な有病率は最大で600人に1人とされています。 現在のカイロミクロン血症の治療は主に、急性膵炎のリスク閾値（<5.7 mmol/L または 500 mg/dL）未満に空腹時トリグリセリド（TG）値を管理することを目的としています。しかし、既存のトリグリセリド低下薬では十分な効果が得られないことが多く、また超低脂肪食は長期的な継続が困難です。
More news about: CorrectSequence Therapeutics
Nov 06, 2025, 20:30 ET La Fundación Michael J. Fox para la Investigación sobre Parkinson celebra a los votantes de Texas por la aprobación de la Proposición 14 que asegura $3 mil millones para la investigación de enfermedades cerebrales
seres queridos que también enfrentan esta enfermedad, he visto lo poderoso que es cuando nuestra comunidad se une para impulsar el cambio", señaló María L. De León, doctora en medicina, residente del este de Texas, especialista en trastornos del movimiento y miembro del Consejo de Pacientes de la MJFF. "La
More news about: The Michael J. Fox Foundation for Parkinson's Research
Nov 06, 2025, 20:00 ET 復星國際榮獲《財資》雜誌頒發的「2025年財資企業永續領導獎金獎」及「最佳可持續發展團隊獎」
全球首個獲批用於一線治療小細胞肺癌的抗PD-1單抗。截至目前，H藥已在中國、歐盟、英國、新加坡、印度等近40個國家和地區獲批上市，惠及全球逾11萬名患者。 今年以來，復星在創新藥領域實現多點破局。HLX43是一款靶向PD-L1的抗體偶聯藥物（ADC），正在中、美、日、澳等國家開展非小細胞肺癌、胸腺癌等實體瘤的臨床研究。目前，全球範圍內尚無PD-L1 ADC獲批上市，HLX43有潛力成為高效、安全的「廣譜抗癌藥」。此外，在小分子創新藥方面，復星自研的靶向藥物復邁寧獲批兩項罕見病適應症，填補了相關罕見病腫瘤領域的治療空白。
More news about: 復星